activated recombinant human factor VII

Phase 2Completed

1 views this week 0 watching💤 Quiet

Interest: 35/100

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

Congenital Bleeding Disorder

Conditions

Congenital Bleeding Disorder, Haemophilia A With Inhibitors, Haemophilia B With Inhibitors

Trial Timeline

Mar 1, 2004 → Nov 1, 2005

NCT ID

NCT00108758

About activated recombinant human factor VII

activated recombinant human factor VII is a phase 2 stage product being developed by Novo Nordisk for Congenital Bleeding Disorder. The current trial status is completed. This product is registered under clinical trial identifier NCT00108758. Target conditions include Congenital Bleeding Disorder, Haemophilia A With Inhibitors, Haemophilia B With Inhibitors.

What happened to similar drugs?

5 of 20 similar drugs in Congenital Bleeding Disorder were approved

Approved (5) Terminated (0) Active (15)

✅turoctocog alfaNovo NordiskApproved

✅eptacog alfa (activated) + Feiba VHNovo NordiskApproved

✅activated recombinant human factor VIINovo NordiskApproved

✅activated recombinant human factor VII + activated recombinant human factor VII + factor VIIINovo NordiskApproved

✅Lipiodol Ultra Fluid with surgical gluesGuerbetApproved

🔄turoctocog alfa + turoctocog alfaNovo NordiskPhase 3

🔄turoctocog alfa pegolNovo NordiskPhase 3

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (17)

NCT ID	Phase	Status	Start	Completion	Indication
NCT01312636	Pre-clinical	Completed	Mar 1, 2011	Sep 1, 2014	Congenital Bleeding Disorder
NCT01285089	Pre-clinical	Completed	Dec 1, 2010	Oct 1, 2013	Acquired Bleeding Disorder
NCT01220141	Pre-clinical	Completed	Nov 1, 2010	Mar 1, 2015	Congenital Bleeding Disorder
NCT01234545	Pre-clinical	Completed	Oct 1, 2010	Apr 1, 2012	Congenital Bleeding Disorder
NCT00853086	Pre-clinical	Completed	Jan 1, 2008	Jun 1, 2011	Congenital Bleeding Disorder
NCT00323570	Phase 3	Withdrawn	May 1, 2006	Jun 1, 2007	Acquired Bleeding Disorder
NCT01562457	Phase 1	Completed	Nov 1, 2005	Apr 1, 2006	Congenital Bleeding Disorder
NCT00123591	Phase 2	Completed	Jan 1, 2005	May 1, 2006	Acquired Bleeding Disorder
NCT00124293	Pre-clinical	Completed	Oct 6, 2004	Nov 23, 2005	Acquired Bleeding Disorder
NCT00154427	Phase 2	Terminated	Aug 1, 2004	Nov 1, 2007	Acquired Bleeding Disorder
NCT00104455	Phase 1	Completed	Jun 1, 2004	Nov 1, 2004	Congenital Bleeding Disorder
NCT00154492	Phase 2	Completed	Apr 1, 2004	Aug 1, 2006	Acquired Bleeding Disorder
NCT00108758	Phase 2	Completed	Mar 1, 2004	Nov 1, 2005	Congenital Bleeding Disorder
NCT01476423	Pre-clinical	Completed	Jan 1, 2004	Oct 1, 2011	Congenital Bleeding Disorder
NCT00571584	Approved	Completed	Nov 1, 2002	Mar 1, 2004	Congenital Bleeding Disorder
NCT00426803	Phase 2	Completed	Aug 1, 2002	Jun 1, 2004	Acquired Bleeding Disorder
NCT01561352	Phase 2	Completed	Sep 1, 2001	Nov 1, 2003	Other Haemostasis Disorder

Competing Products

20 competing products in Congenital Bleeding Disorder

See all competitors

Product	Company	Stage	Hype Score
Tideglusib	AMO Pharma	Pre-clinical	20
Tideglusib + Placebo	AMO Pharma	Phase 2/3	28
Tideglusib	AMO Pharma	Phase 2/3	35
EDIT-101	Editas Medicine	Phase 1/2	18
Tildacerfont/Placebo	Spruce Biosciences	Phase 2	17
SPR001	Spruce Biosciences	Phase 2	25
SPR001	Spruce Biosciences	Phase 2	25
Tildacerfont/Placebo	Spruce Biosciences	Phase 2	17
Tildacerfont	Spruce Biosciences	Phase 2	17
KW-3357	Kyowa Kirin	Phase 1	29
Pasireotide 0.6Mg Solution for Injection + Saline Solution	Novartis	Phase 2	27
Sandostatine LP	Novartis	Phase 2	35
mycophenolate mofetil	Roche	Phase 1	29
turoctocog alfa + turoctocog alfa	Novo Nordisk	Phase 3	40
catridecacog + recombinant factor XIII	Novo Nordisk	Phase 1	29
turoctocog alfa pegol	Novo Nordisk	Phase 3	40
recombinant factor XIII	Novo Nordisk	Pre-clinical	26
activated recombinant human factor VII, long acting + activated recombinant human factor VII, long acting	Novo Nordisk	Phase 1	29
Advate® + turoctocog alfa	Novo Nordisk	Phase 1	29
nonacog beta pegol	Novo Nordisk	Phase 3	40